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Acylation stimulating protein stimulates insulin
secretion
B Ahre´n1*, PJ Havel2, G Pacini3 and K Cianflone4
1Department of Medicine, Lund University, Lund, Sweden; 2Department of Nutrition, University of California, Davis, Ca, USA;
3Metabolic Unit, Institute of Biomedical Engineering, ISIB-CNR, Padua, Italy; and 4Mike Rosenbloom Laboratory for
Cardiovascular Research, Medicine, McGill University, Montreal, Quebec, Canada
Acylation stimulating protein (ASP) is a hormone produced by adipocytes and is of importance for the storage of energy as fat.
We examined whether ASP might also have effects on islet function. In clonal INS-1 cells, ASP dose-dependently augmented
glucose-stimulated insulin secretion. The lowest effective dose of ASP at 10 mmol/l glucose was 5 mmol/l. The effect was glucose-
dependent because ASP did not increase insulin secretion at 1 mmol/l glucose but had clear effect at 10 and 20 mmol/l glucose.
Similarly, ASP augmented glyceraldehyde-induced insulin secretion but the hormone did not enhance insulin secretion in
response to depolarization by 20 mmol/l of KCl. ASP-induced insulin secretion was completely abolished by competitive
inhibition of glucose phosphorylation by glucokinase with 5-thio-glucose and was partially inhibited by the calcium channel
blocker, nifedipine, and by the protein kinase C inhibitor, GF109203. Furthermore, thapsigargin, an inhibitor of Ca2+-ATPase in
the endoplasmic reticulum, did not affect ASP-induced insulin secretion. ASP (45 mmol/l) also augmented glucose-stimulated
insulin secretion from islets isolated from C57BL/6J mice, and intravenous administration of ASP (50 nmol/kg) augmented the
acute (1 and 5 min) insulin response to intravenous glucose (1 g/kg) in C57BL/6J mice. This was accompanied by an increased
rate of glucose disposal. Minimal model analyses of data derived from the intravenous glucose tolerance test revealed that
whereas ASP augmented insulin secretion, the hormone did not affect insulin sensitivity (SI) or glucose effectiveness (SG). We
conclude that ASP augments glucose-stimulated insulin secretion through a direct action on the islet beta cells. The effect is
dependent on glucose phosphorylation, calcium uptake and protein kinase C. Stimulation of insulin secretion by ASP in vivo
results in augmented glucose disposal.
International Journal of Obesity (2003) 27, 1037–1043. doi:10.1038/sj.ijo.0802369
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Introduction
During recent years, it has become evident that adipocytes
express and secrete a number of hormones involved in the
regulation of energy and substrate metabolism including
leptin, adiponectin, resistin and acylation stimulating
protein (ASP).1–3 ASP is a 8.9 kDa hormone produced in the
adipocytes through an interaction of complement factor C3
with factor B and factor D (also called adipsin), which results
in the formation of C3a-des-Arg, also called ASP.4 ASP is
released into the circulation and has been shown to augment
triglyceride synthesis and storage in adipocytes in combina-
tion with stimulation of glucose uptake and diacylglycerol
acyltransferase and inhibition of hormone-sensitive lipase
via phosphodiesterase.5–7 This would suggest that ASP
contributes to the storage of energy as lipids. Such a function
is supported by data indicating that ASP administration
increases triglyceride clearance from plasma,8 and that ASP-
deficient (C3/) mice exhibit delayed postprandial lipid
clearance, reduced adipose tissue depots and are resistant to
obesity induced by high-fat diet.9,10 Involvement by ASP in
the regulation of energy storage is also supported by reports
that plasma levels of ASP are increased in obesity 11 and
reduced in fasting 12 and in postobese women.13 Adipose
tissue release of ASP increases postprandially, with a peak
release observed at 4–5 h after meal ingestion, although
circulating levels remain constant.14
Whether ASP is involved in the regulation of glucose
homeostasis is not known. ASP-deficient mice exhibit
reduced fasting insulin levels and improved glucose
tolerance.9 This would suggest that ASP reduces insulin
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sensitivity. This idea is supported by a study in humans
showing that plasma ASP correlates inversely to glucose
disposal during a euglycemic clamp,15 although this finding
was not reproduced in a subsequent study.16 An effect of ASP
to reduce insulin sensitivity could be explained by its action
to increase triglyceride storage, because intracellular lipid
accumulation in some tissues including liver and muscle is
associated with reduced insulin sensitivity.17,18 In the
present study, we have examined the direct effect of ASP
on insulin secretion in vitro in insulin-producing clonal INS-
1 cells and in isolated mouse islets. In addition, the effects of
ASP on insulin secretion were examined in vivo in C57BL/6J
mice along with the influences of ASP on insulin sensitivity
and on glucose disposal.
Methods
Studies in INS-1 cells
INS-1 cells (kindly provided by Dr C Wollheim, Geneva,
Switzerland) were cultured in plastic flasks ar 371 C in 5%
CO2/95% air in RPMI medium supplemented with 50 mmol/l
mercaptoethanol (GIBCO BRL, Paisley, UK), 2.06 mmol/l
L-gluthamine (Life Technologies, Ta¨by, Sweden), 10% fetal
bovine serum, 100 U/ml penicillin and 2.5 mg/ml amphoter-
icin B (all from Kebo Laboratory, Spa˚nga, Sweden). The cells
were divided after 7 days (about 75% confluence), washed
twice in a HEPES medium containing (in mmol/l) 125 NaCl,
5.9 KCl, 1.28 CaCl2, 1.2 MgCl2, 25 Hepes and 0.1% bovine
serum albumin (pH 7.36). In studies on insulin secretion,
cells were preincubated for 30 min at 371C in 200 ml of the
medium supplemented with 1 mmol/l glucose. Thereafter,
the cells were incubated for 60 min in the medium
supplemented with glucose, glyceraldehyde, nifedipine,
GF109203, thapsigargin with or without addition of ASP
according to the protocols. Following the incubation, 150 ml
of the medium were removed and centrifuged at 350 g for
5 min, whereafter aliquots of 50 ml were saved at 201C until
analysis. GF109203 was purchased from Biomol. Res. Labs.,
Plymoth Meeting, PA, USA. ASP was prepared as described
previously 19 and its purity (99%) was ascertained by ion
spray mass spectrophotometry.20 Other substances and
reagents were from Sigma Chemical Co., St Louis, MO, USA.
Studies in mice
Female C57BL/6J mice, weighing 23.070.3 g, obtained from
the Taconic M&B A/S, Ry, Denmark, were used for this study.
The mice were fed a normal laboratory chow diet and tap
water ad libitum. The study was approved by the Ethics
Committee of Lund University.
Islet studies
Islets were isolated by collagenase digestion, hand-picked
under a stereomicroscope and incubated overnight in RPMI
1640 medium supplemented with 10% fetal calf serum,
100 U/ml penicillin G, 0.1 mg/ml streptomycin and 2.5 mg/
ml amphotericin B. Islets were then incubated in groups of
three in 96-well microtiter plates in a Hepes buffer contain-
ing 3.3, 11.1 or 22.2 mmol/l D-glucose with or without
10 mmol/l ASP. After 60 min incubation at 371C, the super-
natant was collected and stored at –201C until analyzed for
insulin concentration.
In vivo study
The animals were anesthetized with an intraperitoneal
injection of midazolam (0.14 mg/mouse; Dormicums, Hoff-
man-La-Roche, Basel, Switzerland) and a combination of
fluanison (0.28 mg/mouse) and fentanyl (0.02 mg/mouse;
Hypnorms, Janssen, Beerse, Belgium). After 30 min, a blood
sample (75 ml) was taken from the retrobulbar, intraorbital,
capillary plexus in a 100 ml pipette that had been prerinsed in
heparin solution (100 U/ml in 0.9% NaCl; Lo¨vens, Ballerud,
Denmark). Thereafter, D–glucose (British Drug Houses, Poole,
UK) was injected intravenously over 3 s at the dose of 1 g/kg
in a tail vein without flushing of the 27 gauge needle after
injection, either alone or together with ASP (50 nmol/kg
body weight; resulting in a peak level of approximately 5–10
times the circulating level). The injection volume load was
10 ml/g body weight. Additional blood samples (75 ml each)
were collected at 1, 5, 10, 20, 30 and 50 min. Plasma samples
were immediately separated and stored at 201C until
analyzed for insulin and glucose concentrations.
Analyses
Insulin concentration was determined by a double-antibody
radioimmunoassay using guinea pig anti rat insulin anti-
bodies, 125I-labeled human insulin and, as standard, rat
insulin (Linco Res., St Charles, MO, USA). Glucose was
measured by the glucose oxidase technique.
Statistics and calculations
Data and results are reported as means7s.e.m. Statistical
comparisons between the groups were performed with
unpaired Student’s t-test. ANOVA was used for multiple
comparisons. Insulin and glucose data from the intravenous
glucose tolerance test (IVGTT) were analyzed with the
minimal model technique as previously described.21 This
analysis provides parameter SI (insulin sensitivity index),
which is defined as the ability of insulin to enhance net
glucose disappearance and inhibit glucose production, and
the parameter SG, which is the glucose effectiveness,
representing net glucose disappearance per se from plasma
without any change in dynamic insulin. Acute insulin
response (AIR; mean of 1 and 5 min insulin levels after
subtraction of baseline value) and the area under the 50 min
curve of insulin concentration (ie the total insulin response,
AUCinsulin; calculated by the trapezoid rule) were deter-
mined. The glucose tolerance index, KG, was obtained as the
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slope of the logarithmic transformation of the individual
plasma glucose values in the interval 1–20 min after glucose
injection.
Results
Effects of ASP on glucose-stimulated insulin secretion in
INS-1 cells
Glucose-stimulated insulin secretion from INS-1 cells was
augmented by adding ASP to the incubation media. The
effect of ASP was dose-dependent with 5mmol/l being the
lowest effective dose (Figure 1, upper panel). The effect also
required a threshhold concentration of glucose because ASP
did not increase insulin secretion in the presence of 1 mmol/l
glucose but augmented insulin secretion in the presence of
10 or 20 mmol/l glucose (Figure 1, lower panel). ASP also
augmented the insulin response to glyceraldehyde at 10 and
20 mmol/l, but not at 1 mmol/l (Figure 2, upper panel). In
contrast, ASP did not increase insulin secretion elicited by
depolarization by a high concentration of K+ (Figure 2, lower
panel).
To examine whether the insulinotropic action of ASP is
dependent on glucose phosphorylation, cells were incubated
in the presence of 5-thio-glucose (10 mmol/l), which is a
potent competitive inhibitor of glucokinase.22,23 When the
cells were incubated in the presence of 10 mmol/l 5-thio-
glucose, ASP-stimulated insulin secretion was completely
abolished (Figure 3). Furthermore, ASP-induced insulin
secretion was inhibited by approximately 50% by nifedipine
(5 mmol/l), which is a blocker of the L-type Ca2+ channels.24
Thus, in the absence of nifedipine, ASP augmented glucose-
stimulated insulin secretion by 7.470.8 nmol/l and this was
reduced by nifedipine to 4.070.4 nmol/l (Po0.001; Figure 3).
Activation of protein kinase C (PKC) is known to contribute
to glucose-stimulated insulin secretion.25,26 We found that
bisindolylmaleimide (GF109203; 2 mmol/l), which inhibits
PKC,27 inhibited ASP-induced insulin secretion by approxi-
mately 30%. Thus, whereas ASP in the absence of GF109203
augmented glucose-stimulated insulin secretion by
7.570.9 nmol/l, the inhibitor reduced the effect of ASP to
4.870.5 nmol/l (Po0.001). Finally, by combining nifedipine
and GF109203 together, ASP-induced insulin secretion was
completely abolished (Figure 3). In contrast, intracellular
Ca2+ stores do not appear to be required for ASP-induced
insulin secretion, because incubation of the cells with
thapsigargin, which inhibits the Ca2+/ATPase in the endo-
plasmic reticulum thereby depleting the intracellular Ca2+
stores,28 did not affect ASP-induced insulin secretion
(Figure 3).
Effects of ASP on glucose-stimulated insulin secretion in
isolated mouse islets
To examine whether ASP also affects glucose-stimulated
insulin secretion in normal islets, isolated islets from
C57BL/6J mice were incubated in the presence of ASP at
different glucose concentrations. ASP potentiated glucose-
stimulated insulin secretion (Figure 4). The effect showed
similar characteristics to that observed in INS-1 cells, that is,
being glucose-dependent and requiring a threshhold level of
glucose.
Effects of ASP on glucose-stimulated insulin secretion in
mice
To determine whether ASP affects glucose-stimulated insulin
secretion in vivo, anesthetized mice were injected intra-
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Figure 1 Medium insulin concentration after 60 min incubation of INS-1
cells in the presence of 1 or 10 mmol/l glucose with or without addition of ASP
at different concentrations (upper panel) or in the presence of glucose at 1, 10
or 20 mmol/l with or without ASP at 10 mmol/l (lower panel). Means7s.e.m.
are shown. In the upper panel asterisks indicate probability level of random
difference vs 10 mmol/l glucose without ASP (ANOVA with Bonferroni post hoc
analysis) and in the lower panel asterisks indicate probability level of random
difference between groups (Student’s unpaired t-test). *Po0.05, **Po0.01,
***Po0.001. There were 16 incubations in each column.
ASP and insulin secretion
B Ahre´n et al
1039
International Journal of Obesity
venously with glucose alone or in combination with ASP
(50 nmol/kg). ASP augmented the insulin response to glucose
(Figure 5). The effect was rapid in onset and short-lived and
evident during the first 5 min after injection, when the AIR
to glucose was increased from 346746 pmol/l in controls to
571795 pmol/l by ASP (P¼0.042). This resulted in an
increased glucose disposal rate. KG was augmented by ASP
from 2.470.2%/min in controls to 2.970.2%/min
(P¼ 0.033; Table 1). After the initial 5 min exaggeration of
the insulin response to glucose, plasma insulin levels were
slightly lower in the animals that received ASP in combina-
tion with glucose at 20 and 30 min (Po0.05). The total
AUCinsulin throughout the 50 min study period was not
significantly different between the groups. Minimal model
analysis of the glucose and insulin data showed that ASP did
not affect insulin sensitivity (SI) or glucose effectiveness (SG;
Table 1). A significant linear correlation was found between
AIR and KG (r¼0.52, P¼0.010).
Discussion
Previous studies have suggested that the adipocyte-derived
hormone ASP promotes energy storage as lipids through a
direct action on adipocytes.3–10 This study shows that ASP
may be involved also in the regulation of glucose home-
ostasis and islet function because the hormone augments
glucose-stimulated insulin secretion both in vitro and in vivo,
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Figure 2 Medium insulin concentration after 60 min incubation of INS-1
cells in the presence of 1, 10 or 20 mmol/l glyceraldehyde with or without
addition of ASP at 10mmol/l (upper panel) or in the presence of 1 or 10 mmol/
l glucose with or without ASP at 5.9 or 20 mmol/l of KCl (lower panel).
Means7s.e.m. are shown. Asterisks indicate probability level of random
difference between groups (Student’s t-test for unpaired conditions).
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Figure 3 Medium insulin concentration after 60 min incubation of INS-1
cells in the presence of 1 or 10 mmol/l glucose. Incubations at 10 mmol/l
glucose were performed with (black bars) or without (open bars) addition of
ASP at 10 mmol/l. Each panel shows incubations under control conditions (no
inhibitor added) or incubations in the presence of one inhibitor: the inhibitor
of glucokinase, 5-thio-glucose (10 mmol/l; upper left panel), the Ca2+ channel
blocker, nifedipine (5mmol/l; upper right panel), the inhibitor of PKC,
bisindolylmaleimide (GF109203; 2 mmol/l; middle left panel), the combina-
tion of nifedipine and GF109203 (middle right panel) or the inhibitor of Ca2+/
ATPase, thapsigargin (lower left panel). Means7s.e.m. are shown. Asterisks
indicate significance between conditions with vs without ASP, that is,
conditions without and with inhibitor analyzed separately (Student’s t-test
for unpaired conditions). *Po0.05, **Po0.01, ***Po0.001. There were 16–24
incubations in each bar.
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and that this action results in augmentation of glucose
disposal rate under in vivo conditions.
In the clonal INS-1 cells, ASP dose-dependently augmented
insulin secretion in a glucose-dependent manner. This
suggests that ASP augments insulin secretion by promoting
the efficiency of the glucose signaling in the beta cells. In
insulin-producing cells, glucose is taken up and phosphory-
lated. These processes are mediated by the glucose transpor-
ter, GLUT-2, and a high Km hexokinase, type IV
(glucokinase). Glucokinase is of particular importance, being
the ‘glucose sensor’ and the rate-limiting step in glucose-
stimulated insulin secretion.29 As a tool to examine whether
this process is required also for the ASP-induced potentiation
of glucose-stimulated secretion, we used 5-thio-glucose,
which is known to inhibit glucokinase in beta cells.23 We
found that 5-thio-glucose abolished ASP-induced insulin
secretion. Since glyceraldehyde-induced insulin secretion
was also potentiated by ASP, our results imply that ASP
augments insulin secretion by generating a signal down
stream of glyceraldehyde-3-phosphate.
Our results further implicate two separate mechanisms in
the effects of ASP to stimulate insulin secretion. A first step is
the uptake of Ca2+ through opening of L-type Ca2+ channels,
because nifedipine, which blocks these Ca2+ channels in beta
cells,24 inhibited ASP-induced insulin secretion by approxi-
mately 50%. The Ca2+ channels are normally opened by
depolarization instituted by ATP-induced closure of KATP
channels.25 ASP may thus augment insulin secretion
through opening of Ca2+ channels by increasing the
generation of ATP. However, also in the presence of
nifedipine, a considerable fraction (E50%) of the ASP-
induced insulin secretion remained intact. We found that
this remaining ASP-induced insulin secretion was inhibited
by GF109203, which is an inhibitor of classical PKC
subtypes.27 PKC is involved in insulin secretion by first
being activated by glucose through diacylglycerol formed
after phosphoinositide hydrolysis instituted by phospholi-
pase C, and then translocated to the cell membrane and
activating the exocytosis of insulin.26 The results thus
suggest that ASP stimulates insulin secretion by augmenting
the action of glucose to open Ca2+ and to activate PKC.
Interestingly, these effects resemble the actions of ASP in
adipocytes, where the hormone has been shown to enhance
glucose uptake through translocation of glucose transporters
by a mechanism involving translocation and activation of
PKC.4,30–32 In contrast, release of Ca2+ from intracellular
stores does not seem to be a mechanism of ASP in beta cells,
because depletion of Ca2+ stores with thapsigargin28 did not
affect ASP-induced insulin secretion. The involvement of
proximal mechanisms for ASP-induced insulin secretion is
also supported by the results that the hormone was unable to
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Figure 4 Medium insulin concentration after 60 min incubation of isolated
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without ASP at 10mmol/l as indicated. Means7s.e.m. are shown. Asterisks
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Figure 5 Plasma glucose and insulin levels before and after the i.v. injection
of glucose (1 g/kg) alone or together with ASP (50 nmol/kg) in anesthetized
mice. Means7s.e.m. are shown. Asterisks indicate the probability level of
random difference between the groups (Student’s t-test for unpaired
conditions). *Po0.05, **Po0.01. There were 12 animals in each group.
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augment insulin secretion stimulated by high K+. Stimula-
tion by K+ bypasses the proximal effects of glucose and
increases an uptake of Ca2+ through a direct depolarization
effect, which is a KATP channel-independent pathway.
25,33
We also found that ASP augments insulin secretion in vivo
in mice. Intravenous administration of ASP in combination
with glucose during an IVGTT potentiated glucose-stimu-
lated insulin secretion. The effect was rapid in onset and
observed within 1 min after administration. This augmented
glucose-stimulated insulin secretion resulted in increased
rate of glucose disposal. This induced slightly lower glucose
levels at the later time points during the IVGTT, and is likely
to explain the reduced plasma insulin levels at these later
time points. The use of the minimal model analysis of the
data obtained from the IVGTT also allowed us to investigate
the potential influence of ASP on insulin sensitivity and
glucose effectiveness, that is, the glucose disappearance
independent of any dynamic change of insulin.21 The
analysis revealed, however, that these parameters were not
affected by ASP. Therefore, the augmented glucose disposal
seen after administration of ASP appears to be mediated by
the increased insulin secretion. Our finding that ASP did not
affect insulin sensitivity might seem to contradict earlier
observations that plasma ASP levels in humans correlate
inversely to glucose disposal during a euglycemic clamp 15
and that ASP-deficient mice exhibit reduced plasma insulin
levels as a sign of increased insulin sensitivity.9 However, it
has to be emphasized that during chronic studies the action
of ASP to alter triglyceride stores and adipose tissue mass
might indirectly influence insulin sensitivity, an action
which may be distinct from direct actions observed after
short-term administration of the hormone.
In summary, the results presented here provide evidence
that, in addition to its involvement in the local regulation of
lipid formation in adipocytes,3–10 ASP may also have a role in
the regulation of islet function by augmenting glucose-
stimulated insulin secretion via a direct action on the beta
cells. This highlights an interaction between the adipocytes
and the regulation of islet function.34 Furthermore, in
addition to promoting glucose uptake and utilization,
insulin also prominently inhibits lipolysis in adipocytes.35
Therefore, based on the available data, the main actions of
ASP appear to be its effects to promote energy storage as
lipids, both directly to stimulate lipid synthesis in adipo-
cytes,5–7 and indirectly by promoting insulin secretion and
thereby inhibiting lipolysis. Further studies will be required
to examine whether perturbations of this regulation may be
involved in metabolic disorders, such as diabetes and obesity.
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